Top Abstract Purchase Preview Related
Home
>
Node
>
Subnode

Pharmacokinetics of ofloxacin in healthy subjects and patients with varying degrees of renal impairment

Flor, S.; Guay, D.; Opsahl, J.; Tack, K.; Matzke, G.

International Journal of Clinical Pharmacology Research 11(3): 115-121

1991

ISSN/ISBN: 0251-1649
PMID: 1809697
Document Number: 717
The pharmacokinetics of the new fluoroquinolone antimicrobial ofloxacin were studied in 18 subjects with normal renal function or varying degrees of renal impairment, including patients under-going continuous ambulatory peritoneal dialysis (CAPD) and haemodialysis. Apparent total body and renal clearances declined and elimination half-life increased with decreasing creatinine clearance. CAPD and haemodialysis removed clinically insignificant fractions of ofloxacin body burden over the study period (6-15% and 9-11% of the dose, respectively). The apparent volume of distribution, peak concentration, time to peak concentration, and non-renal clearance were not altered significantly by renal insufficiency. An extended dosing interval of 24-48 h is recommended, depending upon the degree of renal impairment, when creatinine clearance falls below 50 mL/min. In addition, supplemental doses would not appear to be necessary during CAPD and following haemodialysis.

Document emailed within 1 workday
Secure & encrypted payments

Pharmacokinetics of ofloxacin in healthy subjects and patients with varying degrees of renal impairment

De Zeeuw, D.; Remuzzi, G.; Kirch, W. 1997: Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment Journal of Human Hypertension 11(Suppl 2): S37-S42
Agnoli, G.C.; Borgatti, R.; Cacciari, M.; Garutti, C.; Ikonomu, E.; Lenzi, P.; Marinelli, M. 1993: Studies on renal function in healthy women with different degrees of induced potassium depletion. 2). Patterns of hypokalemic renal dysfunction Bollettino della Societa Italiana di Biologia Sperimentale 69(9): 557-562
Rovei, V.; Leroy, A.; Sauvanet, J.P.; Braithwaite, R.; Coquelin, J.P.; Gomeni, R.; Morselli, P.L.; Fillastre, J.P. 1981: Comparative pharmacokinetics of antrafenine in healthy volunteers and in patients with chronic renal failure Therapie 36(1): 21-26
Martin, C.; Lambert, D.; Bruguerolle, B.; Saux, P.; Freney, J.; Fleurette, J.; Meugnier, H.; Gouin, F. 1991: Ofloxacin pharmacokinetics in mechanically ventilated patients Antimicrobial Agents and Chemotherapy 35(8): 1582-1585
Walther, H.; Meyer, F.P. 1980: Effect of phenobarbital on self-ratings of healthy subjects in comparison to the objective impairment of their performance Acta Biologica et Medica Germanica 39(8-9): 949-960
Premel-Cabic, A.; Chaleil, D.; Bonniot, R.; Riberi, P.; Streichenberger, G.; Allain, P. 1981: Comparative study of alminoprofene elimination in healthy subjects and in patients with renal or hepatic insufficiency Therapie 36(1): 41-46
Macgregor, D.A.; Smith, T.E.; Prielipp, R.C.; Butterworth, J.F.; James, R.L.; Scuderi, P.E. 2000: Pharmacokinetics of dopamine in healthy male subjects Anesthesiology 92(2): 338-346
Wittayalertpanya, S.; Chompootaweep, S.; Thaworn, N. 2006: The pharmacokinetics of pioglitazone in Thai healthy subjects Journal of the Medical Association of Thailand 89(12): 2116-2122
Chan, M.K.; Chau, P.Y.; Chan, W.W. 1987: Ofloxacin pharmacokinetics in patients on continuous ambulatory peritoneal dialysis Clinical Nephrology 28(6): 277-280
Degen, J.; Wölke, E.; Seiberling, M.; Pintar, P.; Höxter, G.; Steinhauer, H.B.; Fischer, W. 1993: Comparative study of the pharmacokinetics of amitriptyline oxide and trimipramine after single administration in healthy male probands and patients with renal failure Medizinische Klinik 88(3): 129-133; 171
Lal, J.; Asthana, O.P.; Nityanand, S.; Gupta, R.C. 1995: Pharmacokinetics of centchroman in healthy female subjects after oral administration Contraception 52(5): 297-300
Wei, X.; Ding, L.; Gao, J-min.; Li, J.; Zhang, S-qiang.; Shen, J-ping.; Zhang, Y-di. 2004: Pharmacokinetics and bioequivalence of eperisone hydrochloride tablet in healthy subjects Yao Xue Xue Bao 39(4): 309-311
Sudo, R.T.; Melo, P.A.; Suarez-Kurtz, G. 1990: Pharmacokinetics of oral ciprofloxacin in healthy, young Brazilian subjects Brazilian Journal of Medical and Biological Research 23(12): 1315-1321
Carrasco-Portugal, M.C.; Granados-Soto, V.; Reyes-García, G.; Medina-Santillán, R.; Herrera, J.E.; Flores-Murrieta, F.J. 2001: Multiple-dose pharmacokinetics of fluoxetine in healthy Mexican subjects Proceedings of the Western Pharmacology Society 44: 69-70
Jiang, H.; Ding, L.; Yang, J.; Huang, X.; Liu, G-yu.; Zhang, Z-xing. 2004: Pharmacokinetics and bioequivalence of trimebutine dispersive tablet in healthy subjects Yao Xue Xue Bao 39(3): 208-211
Laher, M.S.; Mulkerrins, E.; Hosie, J.; Connell, P.A.; Smith, R.P.; Swaisland, A.J. 1991: The effects of age and renal impairment on the pharmacokinetics of co-administered lisinopril and hydrochlorothiazide Journal of Human Hypertension 5(Suppl 2): 77-84
Weiler, H.; Weiler, C.; Gerok, W. 1990: Gastric mucosal prostaglandin E2 levels in gastric non-ulcer and ulcer patients with chronic renal failure or without renal disease, and in healthy subjects Netherlands Journal of Medicine 37(5-6): 189-196
S, S.; A, A.; Laxmegowda 2016: A study of renal impairment in HIV seropositive subjects in tertiary hospital Journal of the Association of Physicians of India 64(1): 113-113
Witte, P.U.; Irmisch, R.; Hajdú, P. 1985: Pharmacokinetics of pheniramine (Avil) and metabolites in healthy subjects after oral and intravenous administration International Journal of Clinical Pharmacology Therapy and Toxicology 23(1): 59-62
Yamaguchi, T.; Hashizume, T.; Matsuda, M.; Sakashita, M.; Fujii, T.; Sekine, Y.; Nakashima, M.; Uematsu, T. 1994: Pharmacokinetics of the H1-receptor antagonist ebastine and its active metabolite carebastine in healthy subjects Arzneimittel-Forschung 44(1): 59-64